Sustained-release preparation containing metformin hydrochloride and glimepiride and preparation process thereof

A technology of metformin hydrochloride and sustained-release preparations, which is applied in the fields of non-active ingredient medical preparations, pill delivery, pharmaceutical formulations, etc.

Inactive Publication Date: 2007-07-11
BEIJING RUNDEKANG MEDICAL TECH CO LTD
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, there have been patents for common preparations with metformin hydrochloride and glimepiride as active ingredients, but only common preparations
There are no relevant literature and patent reports on the compound metformin hydrochloride glimepiride sustained-release preparation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Embodiment 1 metformin hydrochloride glimepiride double-layer sustained-release tablet

[0018] prescription:

[0019]

[0020] Metformin Hydrochloride 500g

[0021] HPMC-15M 150g

[0022] EC 20g

[0023] Microcrystalline Cellulose 80g

[0024]

[0025] Glimepiride 1g

[0026] 30% acrylic resin IV ethanol solution appropriate amount

[0027] Talc powder 5g

[0028] Appropriate amount of purified water

[0029] A total of 1000 pieces were made

[0030]

[0031] Preparation:

[0032] Pass metformin hydrochloride through a 100-mesh sieve, HPMC-15M and microcrystalline cellulose (30g) pass through a 60-mesh sieve, mix the raw and auxiliary materials evenly, use 30% acrylic resin IV ethanol solution to make a soft material, granulate with a 16-mesh sieve, and dry at 40°C , granulate with 16 mesh sieve, add talc powder and mi...

Embodiment 2

[0033] Example 2 Compound metformin hydrochloride glimepiride film-coated sustained-release tablet

[0034] prescription:

[0035]

[0036] Metformin Hydrochloride 500g

[0037]

[0038] Glimepiride 2g

[0039]

[0040] Microcrystalline Cellulose 250g

[0041] Talc powder 4g

[0042] Appropriate amount of purified water

[0043] Aqueous dispersion of ethyl cellulose Appropriate amount

[0044] A total of 1000 pieces were made

[0045]

[0046] Preparation:

[0047] Pass metformin hydrochloride and glimepiride through a 100-mesh sieve, and set aside; take metformin hydrochloride, mix evenly with microcrystalline cellulose, use purified water to make a soft material, granulate with a 20-mesh sieve, dry, and granulate with a 18-mesh sieve; add talc powder, mix evenly, and press in...

Embodiment 3

[0048] Example 3 Compound Metformin Hydrochloride Glimepiride Sustained Release Pellet Capsules

[0049] prescription:

[0050]

[0051] Metformin Hydrochloride 250g

[0052]

[0053] Glimepiride 0.5g

[0054] HPMC-K100 140g

[0055] Ethylcellulose 25g

[0056] Microcrystalline Cellulose 35g

[0057] Acrylic resin EPO (gastric solution) 12g

[0058]

[0059]

[0060] Talc powder 3g

[0061] 95% ethanol solution appropriate amount

[0062] 50% ethanol solution appropriate amount

[0063]A total of 1000 capsules were made

[0064]

[0065] Preparation:

[0066] Pass metformin hydrochloride and glimepiride through a 100-mesh sieve, and set aside; take metformin hydrochloride, mix with HPMC-K100, microcrystalline cellulose, ethyl cell...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a method for preparing slow-release agent which contains diguanil and gelimourea, wherein said slow-release agent is formed by slow-releaser and quick-releaser; the diguanil is slow-release part which will release 15-40% in first hour, and release 50-70% in fourth hour, and more than 75% at eighth hour; the gelimourea is quick-release component which will release more than 75% after 30min. The invention can avoid side effect and reduce feeding time. And gelimourea can quickly release to improve treatment and reduce blood sugar. The invention also provides relative external release property.

Description

technical field [0001] The invention relates to a compound preparation composed of two hypoglycemic drugs glimepiride and metformin hydrochloride, a compound slow-release preparation for treating type II diabetes that cannot effectively control blood sugar by diet control and exercise and a preparation method thereof . Background technique [0002] This compound is composed of two hypoglycemic drugs, but their mechanism of action is different. The two complement each other. [0003] Metformin hydrochloride does not promote insulin secretion. Its hypoglycemic effect is mainly to promote the uptake of glucose by adipose tissue, increase the anaerobic glycolysis of muscle tissue, increase the utilization of glucose, and reduce the absorption of glucose through the digestive tract. [0004] Glimepiride is a new generation of sulfonylurea (SU) oral hypoglycemic drugs. The main mechanism of its hypoglycemic effect is to bind to the SU receptor on the surface of insulin β cells, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/40A61K9/16A61K9/20A61K9/22A61K9/52A61K47/10A61K47/14A61K47/32A61K47/36A61K47/38A61K47/44A61P3/10A61K31/155
Inventor 李胜飞
Owner BEIJING RUNDEKANG MEDICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products